GU Cancer Clinical Trials

UCI 16-19 ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy (Uchio)

“SUSPENDED” UCI 16-76 Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) (Mar)

UCI 17-10 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/ Prednisolone, Relative to Placebo plus Abiraterone plus Prednisone/ Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer (Mar)

UCI 17-25** A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/ Prednisone) (Uchio)

UCI 17-41** A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) (Uchio)

UCI 17-86 Phase 1 Trial of Efficacy and Feasibility of Robot Assisted Salvage Pelvic Lymph Node Dissection (RS-PLND) or Robot Assisted Salvage Pelvic Mass Resection (RS-PMR) Post-Robot Assisted Radical Prostatectomy (Ahlering)

Non-Metastatic

Metastatic

Both

**Opening soon

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

Version 05/18
For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**Opening soon**

**Epidemiologic**

UCI 15-70 Small Nucleolar RNAs (snoRNAs) And Alternative Splicing In Castration-Resistant Prostate Cancer: A Potential Role In Regulation Of Androgen Receptor Signaling (Zi)

UCI 00-55 Retrospective Evaluation of Prostate Cancer Clinical and Pathological Outcomes (Ahlering)

UCI 06-13 Evaluation of Predictive Signatures of Prostate Cancer (Mercola)

UCI 98-41 Outcomes and Assessment of Prostate Cancer at UCIMC (Ahlering)

**Observational**

UCI 17-40 Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response (Uchio)

**Prevention**

UCI 14-90 Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading (Mercola)
For more details contact 1-877-UC-STUDY or ucstudy@uci.edu
**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

Version 05/18
GU Cancer Clinical Trials

Prostate/Renal

UCI 16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)

Prostate/Bladder

UCI 17-90 A Two-Part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients with HER2-Positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy (Ou)

ECOG EAY131 Molecular Analysis for Therapy Choice (MATCH) (Bota)

SWOG S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)
- 17: Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis
- 18: Squamous cell carcinoma variants of the GU system
- 19: Spindle cell carcinoma of kidney, pelvis, ureter
- 33: NOC Rare Tumors, after discussion with Study Chairs

UCI 16-96 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

UCI 17-50 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)

UCI 07-40 Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Ou)

ECOG EAY131 Molecular Analysis for Therapy Choice (MATCH) (Bota)

**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

Version 05/18